Univest
Univest
  • Markets
  • Cipla vs Lupin 2027: Same Rs 29,000 Cr Revenue

    • November 17, 2026
    • Posted by: Ankit Jaiswal
    • Category: Market
    No Comments
    Cipla vs Lupin 2027: Same Rs 29,000 Crore Revenue, Very Different Profits and Valuations

    Cipla vs Lupin 2027: both reported about Rs 29,040 crore of FY26 revenue, yet Lupin earned Rs 5,356 crore of profit against Rs 3,870 crore for Cipla and trades at less than half its P/E. Here is the full comparison.

    read more
  • Aarti Pharmalabs Analyst Review 2027

    • November 17, 2026
    • Posted by: Kunal Singla
    • Category: Market
    No Comments
    Aarti Pharmalabs Analyst Review 2027: Profit Up 2.5 Times in a Year as the Stock Nears a Record

    Aarti Pharmalabs posted record Q2 FY27 revenue of ₹610 crore with EBITDA up 80% and profit more than doubling. With no current dated brokerage target, we review the recovery, CDMO and xanthine plans, valuation and risks for 2027.

    read more
  • Aarey Drugs Analyst Review 2027

    • November 17, 2026
    • Posted by: Kunal Singla
    • Category: Market
    No Comments
    Aarey Drugs Analyst Review 2027: A Stock That Doubled on a Business Earning ₹1.37 Crore a Quarter

    Aarey Drugs & Pharmaceuticals has more than doubled from its 52-week low, yet it earned just ₹1.37 crore in Q2 FY27 and has no brokerage coverage. We look at the numbers behind the rally, margins, valuation and risks for 2027.

    read more
  • Alkem Laboratories Analyst Review 2027: Sales Up 14%, Profit Down 12%, and a Tax Rate That Tripled

    • November 17, 2026
    • Posted by: Kunal Singla
    • Category: Market
    No Comments
    Alkem Laboratories Analyst Review 2027: Sales Up 14%, Profit Down 12%, and a Tax Rate That Tripled

    Alkem grew Q2 FY27 revenue 13.8% and EBITDA 11.3%, yet profit fell 11.7% as its tax rate jumped to 33%. We review five brokerage targets from ₹4,638 to ₹6,890, the India and export businesses, and the risks for 2027.

    read more
  • Abbott India Analyst Review 2027: A 38.7% ROE, a 2.5% Dividend Yield and Targets Up to ₹36,457. Why Is the Stock Flat?

    • November 17, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Abbott India Analyst Review 2027: A 38.7% ROE, a 2.5% Dividend Yield and Targets Up to ₹36,457. Why Is the Stock Flat?

    Abbott India pairs a 38.7% ROE and near-zero debt with a 2.5% dividend yield, yet the stock sits near its 52-week low. We cover targets from ICICI Securities and BOB Capital, Q2 FY27 numbers, the brand model and 2027 triggers.

    read more
  • Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Which Stock Should You Track

    • September 23, 2026
    • Posted by: Harsh Piplani
    • Category: Market
    No Comments
    Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma: Which Stock Should You Track

    Aurobindo Pharma vs AstraZeneca Pharma India vs Bal Pharma compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of September 2026.

    read more
  • 1
  • 2